Network Pharmacology-Based Investigation of Astragalus Protection in Myocardial Ischemia-Reperfusion Injury
Abstract
(MIRI) through a network pharmacology strategy. Methods: Candidate constituents of Astragalus and their putative targets were obtained
from TCMSP, PubChem, SwissTargetPrediction, and related literature. Disease targets for MIRI were collected from GeneCards, OMIM, and
DrugBank, followed by de-duplication and overlap analysis. The shared targets were submitted to STRING for protein-protein interaction (PPI)
analysis and then visualized in Cytoscape 3.9.0, where hub genes were screened with cytoHubba. Metascape was used for GO and KEGG enrichment, and Cytoscape was further applied to build a constituent-target-pathway network. Results: Twenty-one candidate active constituents
and 208 predicted Astragalus-related targets were obtained. Comparison with the disease-target set identified 127 shared targets. IL6, AKT1,
VEGFA, and other genes appeared as important nodes in the PPI network. Enrichment analysis returned 2, 127 biological process terms, 93
cellular component terms, 152 molecular function terms, and 331 KEGG pathways. Conclusion: Quercetin, kaempferol, and isorhamnetin
may be the principal active constituents of Astragalus in MIRI. Their effects are likely related to targets such as MAPK1, AKT1, and IL6 and
to pathways including fluid shear stress and atherosclerosis, PI3K-Akt, IL-17, HIF-1, and AGE-RAGE signaling. The results offer a networkbased reference for later experimental verification of Astragalus in MIRI.
Keywords
Full Text:
PDFReferences
[1] Hu Shengshou, Gao Runlin, Liu Lisheng. Summary of the Report on Cardiovascular Diseases in China 2018 [J]. Chinese Circulation
Journal, 2019, 34(3): 209-220.
[2] Zhao J, Gao JL, Zhu JX, et al. The different response of cardiomyocytes and cardiac fibroblasts to mitochondria inhibition and the underlying role of STAT3. Basic Res Cardiol 2019;114:12-28.
[3] Davidson SM, Arjun S, Basalay MV, et al. The 10th Biennial Hatter Cardiovascular Institute workshop: cellular protection-evaluating
new directions in the setting of myocardial infarction, ischaemic stroke, and cardio-oncology. Basic Res Cardiol 2018;113:43-54.
[4] Yang Xiao, Zhang Ruifen. Progress in experimental research on the treatment of myocardial ischemia-reperfusion injury with Traditional Chinese Medicine [J]. Acta Chinese Medicine and Pharmacology, 2019, 47(1): 120-123.
[5] Li Ji, Ding Ying, Wang Chengxiang. A brief discussion on new developments in Traditional Chinese Medicine regarding myocardial
ischemia-reperfusion injury [J]. Acta Chinese Medicine and Pharmacology, 2016, 44(2): 105-107.
[6] Li Hui, Zhu Tianmin. A brief analysis of the etiology and pathogenesis of myocardial ischemia-reperfusion injury in Traditional Chinese
Medicine [J]. Lishizhen Medicine and Materia Medica Research, 2012, 23(2): 434-435.
[7] Liu Zhenhua, Zhang Yanhong, Dong Jie. Quercetin reduces myocardial ischemia/reperfusion microvascular permeability by upregulating SIRT1 [J]. Chinese Journal of Pathophysiology. 2020, 36(04):644-651.
[8] Tang Xilan, Liu Jianxun, Li Peng. Protective effects of kaempferol and quercetin on myocardial hypoxia-reoxygenation and oxidative
damage in suckling rats [J]. Chinese Materia Medica Pharmacology and Clinical Practice. 2012, 28(01):56-59.
[9] He Yijin, Zhang Pengzhi, Tian Haiyue. Effect of quercetin on anti-hypoxic damage of H9C2 cells through the MAPK/ERK1/2 signaling
pathway [J]. Journal of the Third Military Medical University, 2021, 43(20):2220-2225.
[10] FERN NDEZ-HERNANDO C, J ZSEF L, JENKINS D, et al.
DOI: http://dx.doi.org/10.70711/pmr.v3i9.9889
Refbacks
- There are currently no refbacks.
